Our study, for the first time to our knowledge, demonstrated that H-FABP was a useful predictor for adverse clinical outcomes in pre-diabetic patients with CAD, suggesting that elevation of H-FABP might provide prognostic information in CAD patients with mild abnormal glucose metabolism. This evidence concerns the gene FABP3 and coronary artery disorder.